Hutchison China MediTech Limited Stock London S.E.
Equities
KYG4672N1198
Pharmaceuticals
Sales 2024 * | 681M 0 | Sales 2025 * | 836M 0 | Capitalization | 3.14B 0 |
---|---|---|---|---|---|
Net income 2024 * | -109M - | Net income 2025 * | -6M - | EV / Sales 2024 * | 4.32 x |
Net cash position 2024 * | 199M 0 | Net cash position 2025 * | 306M 0 | EV / Sales 2025 * | 3.4 x |
P/E ratio 2024 * |
-26.6
x | P/E ratio 2025 * |
560
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
Latest transcript on Hutchison China MediTech Limited
Managers | Title | Age | Since |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 04-12-31 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 08-06-30 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 99-12-31 |
Graeme Jack
BRD | Director/Board Member | 73 | 17-02-28 |
Dan Eldar
BRD | Director/Board Member | 70 | 16-07-31 |
1st Jan change | Capi. | |
---|---|---|
+25.37% | 672B | |
+25.87% | 570B | |
-5.15% | 360B | |
+16.68% | 321B | |
+8.33% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.70% | 149B |